Economic Burden of Prostate Cancer Overall and by Stages Based on the French Real-World Nationwide Medico-Administrative Database (SNDS)
Author(s)
Stephane Supiot, MD1, Jean emmanuel Bibault, MD2, Alice Brouquet, MSc3, Helene Denis, PharmD3, Eleonore Herquelot, PhD3, Baptiste Pitel, MSc3, Pierre M. Touminet, MD4, Laurène Gautier, MSc4, Thilina Kariyawasam, MSc4, Bertrand Lukacs, MD5, Yann Neuzillet, MD6.
1Institut de cancérologie de l'OUEST, Nantes, France, 2Hopital Européen Georges Pompidou, Paris, France, 3Heva, Lyon, France, 4J&J Innovative Medicine, Issy-les-Moulineaux, France, 5Observapur, Paris, France, 6Hopital Foch, Paris, France.
1Institut de cancérologie de l'OUEST, Nantes, France, 2Hopital Européen Georges Pompidou, Paris, France, 3Heva, Lyon, France, 4J&J Innovative Medicine, Issy-les-Moulineaux, France, 5Observapur, Paris, France, 6Hopital Foch, Paris, France.
OBJECTIVES: Prostate cancer is an important disease in terms of economic implications due to the increase of incidence and health-care costs. The goal of this real-life study was to provide estimation of the economic burden of patients managed for prostate cancer in France, overall and by stages.
METHODS: This observational nationwide cohort study includes all patients with prostate cancer identified between 2015 and 2019 in the French National health database (SNDS). Reimbursed costs for each year of follow-up (Fup) were estimated from the perspective of the French National Health Insurance, overall and by main type of costs for incident patients during the Fup. This abstract focuses on patients with localized (LPC) stages including LPC treated as high-risk (LPC HR), LPC treated as non-HR (LPC non-HR), LPC untreated (LPC NT), and patients in advanced stages.
RESULTS: The mean (+/-sd) total cost during the first year of Fup was : €29,440.8 (+/-46,333.8) in advanced stages versus €25,890.3 (+/-46,749.6) in early stages (€32,336.8 (+/-30,294.1) for LPC-HR, €27,378.5 (+/-32,797.5) for LPC non-HR and €20,955.8 (+/-59,026.2) for LPC NT). Costs significantly drop over years of Fup (ex: costs divided by 2 for advanced stages and divided by 3 for early stages during the 3rd year of Fup. For all stages, most costs were related to hospitalizations. For advanced stages, the second most important type of cost was related to medications reimbursed outside the hospital (representing in average €5,488.5 (+/-11,351.8) versus €1,859.4 (+/-3,653.0) in early stages. It was followed by outpatient medical procedure costs averaging €3,583.1 (+/-9,585.1) for early stages and €3,153.1 (+/-7,771.1) for advanced stages.
CONCLUSIONS: Whereas higher reimbursed costs were observed during the first year of follow-up for LPC-HR, they significantly dropped during the Fup showing a strong interest in improving oncological outcomes for patients with a higher risk of progression.
METHODS: This observational nationwide cohort study includes all patients with prostate cancer identified between 2015 and 2019 in the French National health database (SNDS). Reimbursed costs for each year of follow-up (Fup) were estimated from the perspective of the French National Health Insurance, overall and by main type of costs for incident patients during the Fup. This abstract focuses on patients with localized (LPC) stages including LPC treated as high-risk (LPC HR), LPC treated as non-HR (LPC non-HR), LPC untreated (LPC NT), and patients in advanced stages.
RESULTS: The mean (+/-sd) total cost during the first year of Fup was : €29,440.8 (+/-46,333.8) in advanced stages versus €25,890.3 (+/-46,749.6) in early stages (€32,336.8 (+/-30,294.1) for LPC-HR, €27,378.5 (+/-32,797.5) for LPC non-HR and €20,955.8 (+/-59,026.2) for LPC NT). Costs significantly drop over years of Fup (ex: costs divided by 2 for advanced stages and divided by 3 for early stages during the 3rd year of Fup. For all stages, most costs were related to hospitalizations. For advanced stages, the second most important type of cost was related to medications reimbursed outside the hospital (representing in average €5,488.5 (+/-11,351.8) versus €1,859.4 (+/-3,653.0) in early stages. It was followed by outpatient medical procedure costs averaging €3,583.1 (+/-9,585.1) for early stages and €3,153.1 (+/-7,771.1) for advanced stages.
CONCLUSIONS: Whereas higher reimbursed costs were observed during the first year of follow-up for LPC-HR, they significantly dropped during the Fup showing a strong interest in improving oncological outcomes for patients with a higher risk of progression.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
RWD72
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Oncology, Urinary/Kidney Disorders